VAV1

Insilico Medicine has nominated an AI-designed VAV1 molecular glue degrader as a preclinical drug candidate for the treatment of autoimmune diseases. The nomination marks another step in the company's strategy of using generative artificial intelligence to discover and design novel therapeutics, and the candidate will now move forward into further development.